Particle.news
Download on the App Store

Daily Coffee Linked to 39% Fewer AF Recurrences in Randomized Trial

The JAMA-published DECAF study suggests clinicians can consider personalized guidance for habitual coffee drinkers after cardioversion.

Overview

  • In the DECAF trial, 200 adults with atrial fibrillation were randomized after cardioversion to drink at least one cup of caffeinated coffee daily or avoid all caffeine for six months.
  • Recurrent atrial fibrillation or flutter occurred in 47% of the coffee group versus 64% of the no-caffeine group, reflecting a 39% lower risk with coffee.
  • Results were presented at the American Heart Association Scientific Sessions and published in JAMA on the same day.
  • Participants were mostly older, male, and white habitual coffee drinkers, and the study did not track exercise, diet, or effects of other caffeinated beverages.
  • About one-third of those assigned to avoid caffeine reported at least one cup during the study, a nonadherence that tempers broad conclusions while still challenging blanket caffeine-avoidance advice.